Literature DB >> 20567945

An update on the neurologic applications of botulinum toxins.

Virgilio Gerald H Evidente1, Charles H Adler.   

Abstract

Initially used to treat strabismus in the 1970s, botulinum toxin now has more than a hundred possible medical applications. Its utility in neurologic conditions has largely involved treating movement disorders (particularly dystonia and conditions with muscle hyperactivity), although practically any hyperkinetic movement disorder may be relieved by botulinum toxin, including hemifacial spasm, tremor, tics, myoclonus, and spasticity. Although initially thought to inhibit acetylcholine release only at the neuromuscular junction, botulinum toxins are now recognized to inhibit acetylcholine release at autonomic cholinergic nerve terminals, as well as peripheral release of neurotransmitters involved in pain regulation. Thus, their use in neurology has been expanded to include headache and other pain syndromes, as well as hypersecretory disorders. This article highlights some of the common neurologic conditions currently improved by botulinum toxins and reviews the scientific evidence from research studies and clinical experience with these conditions.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20567945     DOI: 10.1007/s11910-010-0129-z

Source DB:  PubMed          Journal:  Curr Neurol Neurosci Rep        ISSN: 1528-4042            Impact factor:   5.081


  54 in total

1.  Clinical application of botulinum toxin type B in movement disorders and autonomic symptoms.

Authors:  Xin-hua Wan; Kevin Dat Vuong; Joseph Jankovic
Journal:  Chin Med Sci J       Date:  2005-03

2.  Botulinum toxin for writer's cramp: a randomised, placebo-controlled trial and 1-year follow-up.

Authors:  J J M Kruisdijk; J H T M Koelman; B W Ongerboer de Visser; R J de Haan; J D Speelman
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-12-21       Impact factor: 10.154

3.  Botulinum toxin for simple motor tics: a randomized, double-blind, controlled clinical trial.

Authors:  C Marras; D Andrews; E Sime; A E Lang
Journal:  Neurology       Date:  2001-03-13       Impact factor: 9.910

4.  Botulinum toxin type A (BOTOX) for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial.

Authors:  Ninan T Mathew; Benjamin M Frishberg; Marek Gawel; Rozalina Dimitrova; John Gibson; Catherine Turkel
Journal:  Headache       Date:  2005-04       Impact factor: 5.887

5.  Separation, purification, partial characterization and comparison of the heavy and light chains of botulinum neurotoxin types A, B, and E.

Authors:  V Sathyamoorthy; B R DasGupta
Journal:  J Biol Chem       Date:  1985-09-05       Impact factor: 5.157

6.  Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study.

Authors:  Daniel Truong; Drake D Duane; Joseph Jankovic; Carlos Singer; Lauren C Seeberger; Cynthia L Comella; Mark F Lew; Robert L Rodnitzky; Fabio O Danisi; James P Sutton; P David Charles; Robert A Hauser; Geoffrey L Sheean
Journal:  Mov Disord       Date:  2005-07       Impact factor: 10.338

7.  Double-blind controlled study of botulinum toxin in adductor spasmodic dysphonia.

Authors:  D D Troung; M Rontal; M Rolnick; A E Aronson; K Mistura
Journal:  Laryngoscope       Date:  1991-06       Impact factor: 3.325

8.  Assessment: Botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.

Authors:  M Naumann; Y So; C E Argoff; M K Childers; D D Dykstra; G S Gronseth; B Jabbari; H C Kaufmann; B Schurch; S D Silberstein; D M Simpson
Journal:  Neurology       Date:  2008-05-06       Impact factor: 9.910

9.  Randomized double-blind study of botulinum toxin type B for sialorrhea in ALS patients.

Authors:  Carlayne E Jackson; Gary Gronseth; Jeffrey Rosenfeld; Richard J Barohn; Richard Dubinsky; C Blake Simpson; April McVey; Pamela P Kittrell; Ruth King; Laura Herbelin
Journal:  Muscle Nerve       Date:  2009-02       Impact factor: 3.217

Review 10.  Clostridial neurotoxins as tools to investigate the molecular events of neurotransmitter release.

Authors:  G Schiavo; O Rossetto; C Montecucco
Journal:  Semin Cell Biol       Date:  1994-08
View more
  9 in total

Review 1.  Progress in cell based assays for botulinum neurotoxin detection.

Authors:  Sabine Pellett
Journal:  Curr Top Microbiol Immunol       Date:  2013       Impact factor: 4.291

Review 2.  Insights into the mechanism of onabotulinumtoxinA in chronic migraine.

Authors:  Paul L Durham; Roger Cady
Journal:  Headache       Date:  2011 Nov-Dec       Impact factor: 5.887

3.  Structural Features of Clostridium botulinum Neurotoxin Subtype A2 Cell Binding Domain.

Authors:  Kyle S Gregory; Tejaswini B Mahadeva; Sai Man Liu; K Ravi Acharya
Journal:  Toxins (Basel)       Date:  2022-05-19       Impact factor: 5.075

4.  Enhancing the protective immune response against botulism.

Authors:  Amanda Przedpelski; William H Tepp; Abby R Kroken; Zhuji Fu; Jung-Ja P Kim; Eric A Johnson; Joseph T Barbieri
Journal:  Infect Immun       Date:  2013-05-13       Impact factor: 3.441

5.  Characterization of botulinum neurotoxin A subtypes 1 through 5 by investigation of activities in mice, in neuronal cell cultures, and in vitro.

Authors:  Regina C M Whitemarsh; William H Tepp; Marite Bradshaw; Guangyun Lin; Christina L Pier; Jacob M Scherf; Eric A Johnson; Sabine Pellett
Journal:  Infect Immun       Date:  2013-08-05       Impact factor: 3.441

Review 6.  Diverse Physiological Roles of Calcitonin Gene-Related Peptide in Migraine Pathology: Modulation of Neuronal-Glial-Immune Cells to Promote Peripheral and Central Sensitization.

Authors:  Paul L Durham
Journal:  Curr Pain Headache Rep       Date:  2016-08

7.  Endomicroscopy and electromyography of neuromuscular junctions in situ.

Authors:  Rosalind Brown; Kosala N Dissanayake; Paul A Skehel; Richard R Ribchester
Journal:  Ann Clin Transl Neurol       Date:  2014-10-10       Impact factor: 4.511

Review 8.  Botulinum Neurotoxin Therapy for Depression: Therapeutic Mechanisms and Future Perspective.

Authors:  Yang Li; Tong Liu; Weifeng Luo
Journal:  Front Psychiatry       Date:  2021-04-23       Impact factor: 4.157

9.  Crystal Structures of the Clostridium botulinum Neurotoxin A6 Cell Binding Domain Alone and in Complex with GD1a Reveal Significant Conformational Flexibility.

Authors:  Kyle S Gregory; Anna R Newell; Otsile O Mojanaga; Sai Man Liu; K Ravi Acharya
Journal:  Int J Mol Sci       Date:  2022-08-25       Impact factor: 6.208

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.